Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 6/2015

01.06.2015 | Gynecologic Oncology

Personal or first-degree family breast cancer history: which has higher impact on tumor detection and tumor size in breast cancer

verfasst von: Fabienne Dominique Schwab, Nerbil Kilic, Dorothy Jane Huang, Seraina Margaretha Schmid, Marcus Vetter, Andreas Schötzau, Uwe Güth

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 6/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

A woman’s risk of developing breast cancer (BC) is increased if she has a personal history (PH) or family history (FH) of the disease. We compared the impact of the two risk factors PH and FH on tumor detection and tumor size at diagnosis in a cohort of BC patients.

Methods

The study cohort comprised 1,037 invasive BC patients (≤70 years at diagnosis). From these, 92 patients (8.5 %) had a positive PH and 151 patients (13.7 %) had a positive first-degree FH.

Results

Compared to the tumors of patients without PH or FH, the lesions of patients who had a positive PH or a positive FH were more often found by radiologic breast examinations (RBE) (PH: 49.4 %, FH: 43.4 %, no PH/FH: 26.2 %; both comparisons p < 0.001). In patients with a positive FH, the tumors were slightly less often found by RBE as in patients with a positive PH (p = 0.468). Patients with a positive PH or FH had smaller tumors compared with those without such a history (PH: 19.7 mm, FH: 19.6 mm, no PH/FH: 26.7 mm; p = 0.015/p < 0.001). The tumor sizes of patients with a positive PH were almost identical to those of patients with a positive FH (p = 0.999).

Conclusions

In women with a positive FH or PH of BC, the increased awareness of BC risk led to the detection of smaller tumors compared to women who have not had this experience. However, comparison of the two risk factors showed that they had a similar impact on the RBE detection rate of BC lesions and that the tumor sizes were nearly identical.
Literatur
1.
Zurück zum Zitat Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef Collaborative Group on Hormonal Factors in Breast Cancer (2001) Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease. Lancet 358(9291):1389–1399CrossRef
2.
Zurück zum Zitat Colditz GA, Kaphingst KA, Hankinson SE, Rosner B (2012) Family history and risk of breast cancer: nurses’ health study. Breast Cancer Res Treat 133(3):1097–1104CrossRefPubMedCentralPubMed Colditz GA, Kaphingst KA, Hankinson SE, Rosner B (2012) Family history and risk of breast cancer: nurses’ health study. Breast Cancer Res Treat 133(3):1097–1104CrossRefPubMedCentralPubMed
3.
Zurück zum Zitat Kerlikowske K, Carney PA, Geller B, Mandelson MT, Taplin SH, Malvin K, Ernster V, Urban N, Cutter G, Rosenberg R et al (2000) Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Int Med 133(11):855–863CrossRefPubMed Kerlikowske K, Carney PA, Geller B, Mandelson MT, Taplin SH, Malvin K, Ernster V, Urban N, Cutter G, Rosenberg R et al (2000) Performance of screening mammography among women with and without a first-degree relative with breast cancer. Ann Int Med 133(11):855–863CrossRefPubMed
4.
Zurück zum Zitat Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716CrossRefPubMed Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin J et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378(9804):1707–1716CrossRefPubMed
5.
Zurück zum Zitat Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241CrossRefPubMed Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, Jeong JH, Wolmark N (2002) Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 347(16):1233–1241CrossRefPubMed
6.
Zurück zum Zitat Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, Rosenberg PS, Anderson WF (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29(12):1564–1569CrossRefPubMedCentralPubMed Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, Rosenberg PS, Anderson WF (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29(12):1564–1569CrossRefPubMedCentralPubMed
7.
Zurück zum Zitat van Laar C, van der Sangen MJ, Poortmans PM, Nieuwenhuijzen GA, Roukema JA, Roumen RM, Tjan-Heijnen VC, Voogd AC (2013) Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. Eur J Cancer 49(15):3093–3101CrossRefPubMed van Laar C, van der Sangen MJ, Poortmans PM, Nieuwenhuijzen GA, Roukema JA, Roumen RM, Tjan-Heijnen VC, Voogd AC (2013) Local recurrence following breast-conserving treatment in women aged 40 years or younger: trends in risk and the impact on prognosis in a population-based cohort of 1143 patients. Eur J Cancer 49(15):3093–3101CrossRefPubMed
8.
Zurück zum Zitat Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, Fisher B, Wolmark N (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24(13):2028–2037CrossRefPubMed Wapnir IL, Anderson SJ, Mamounas EP, Geyer CE Jr, Jeong JH, Tan-Chiu E, Fisher B, Wolmark N (2006) Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in five National Surgical Adjuvant Breast and Bowel Project node-positive adjuvant breast cancer trials. J Clin Oncol 24(13):2028–2037CrossRefPubMed
9.
Zurück zum Zitat Yang SH, Yang KH, Li YP, Zhang YC, He XD, Song AL, Tian JH, Jiang L, Bai ZG, He LF et al (2008) Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Ann Oncol 19(6):1039–1044CrossRefPubMed Yang SH, Yang KH, Li YP, Zhang YC, He XD, Song AL, Tian JH, Jiang L, Bai ZG, He LF et al (2008) Breast conservation therapy for stage I or stage II breast cancer: a meta-analysis of randomized controlled trials. Ann Oncol 19(6):1039–1044CrossRefPubMed
10.
Zurück zum Zitat Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ et al (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(7):961–965CrossRefPubMed Khatcheressian JL, Hurley P, Bantug E, Esserman LJ, Grunfeld E, Halberg F, Hantel A, Henry NL, Muss HB, Smith TJ et al (2013) Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 31(7):961–965CrossRefPubMed
11.
Zurück zum Zitat Aebi S, Davidson T, Gruber G, Cardoso F (2011) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6)):vi12–vi24PubMed Aebi S, Davidson T, Gruber G, Cardoso F (2011) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 22(Suppl 6)):vi12–vi24PubMed
12.
Zurück zum Zitat Couto E, Banks E, Reeves G, Pirie K, Beral V (2008) Family history and breast cancer tumour characteristics in screened women. Int J Cancer 123(12):2950–2954CrossRefPubMed Couto E, Banks E, Reeves G, Pirie K, Beral V (2008) Family history and breast cancer tumour characteristics in screened women. Int J Cancer 123(12):2950–2954CrossRefPubMed
13.
Zurück zum Zitat Montgomery DA, Krupa K, Cooke TG (2007) Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br Journal Cancer 97(12):1632–1641CrossRef Montgomery DA, Krupa K, Cooke TG (2007) Follow-up in breast cancer: does routine clinical examination improve outcome? A systematic review of the literature. Br Journal Cancer 97(12):1632–1641CrossRef
14.
Zurück zum Zitat Murabito JM, Evans JC, Larson MG, Kreger BE, Splansky GL, Freund KM, Moskowitz MA, Wilson PW (2001) Family breast cancer history and mammography: Framingham Offspring Study. Am J Epidemiol 154(10):916–923CrossRefPubMed Murabito JM, Evans JC, Larson MG, Kreger BE, Splansky GL, Freund KM, Moskowitz MA, Wilson PW (2001) Family breast cancer history and mammography: Framingham Offspring Study. Am J Epidemiol 154(10):916–923CrossRefPubMed
15.
Zurück zum Zitat Schwab FD, Burki N, Huang DJ, Heinzelmann-Schwarz V, Schmid SM, Vetter M, Schotzau A, Guth U (2014) Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer. Fam Cancer 13:99–107CrossRefPubMed Schwab FD, Burki N, Huang DJ, Heinzelmann-Schwarz V, Schmid SM, Vetter M, Schotzau A, Guth U (2014) Impact of breast cancer family history on tumor detection and tumor size in women newly-diagnosed with invasive breast cancer. Fam Cancer 13:99–107CrossRefPubMed
16.
17.
Zurück zum Zitat Tracy KA, Quillin JM, Wilson DB, Borzelleca J, Jones RM, McClish D, Bowen D, Bodurtha J (2008) The impact of family history of breast cancer and cancer death on women’s mammography practices and beliefs. Genet Med 10(8):621–625CrossRefPubMed Tracy KA, Quillin JM, Wilson DB, Borzelleca J, Jones RM, McClish D, Bowen D, Bodurtha J (2008) The impact of family history of breast cancer and cancer death on women’s mammography practices and beliefs. Genet Med 10(8):621–625CrossRefPubMed
18.
Zurück zum Zitat Lijovic M, Davis SR, Fradkin P, Bradbury J, La China M, Schwarz M, Wolfe R, Farrugia H, Bell RJ (2009) The relationship between knowledge of family history and cancer characteristics at diagnosis in women newly-diagnosed with invasive breast cancer. Fam Cancer 8(4):299–305CrossRefPubMed Lijovic M, Davis SR, Fradkin P, Bradbury J, La China M, Schwarz M, Wolfe R, Farrugia H, Bell RJ (2009) The relationship between knowledge of family history and cancer characteristics at diagnosis in women newly-diagnosed with invasive breast cancer. Fam Cancer 8(4):299–305CrossRefPubMed
19.
Zurück zum Zitat Malone KE, Daling JR, Doody DR, O’Brien C, Resler A, Ostrander EA, Porter PL (2011) Family history of breast cancer in relation to tumor characteristics and mortality in a population-based study of young women with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 20(12):2560–2571CrossRefPubMedCentralPubMed Malone KE, Daling JR, Doody DR, O’Brien C, Resler A, Ostrander EA, Porter PL (2011) Family history of breast cancer in relation to tumor characteristics and mortality in a population-based study of young women with invasive breast cancer. Cancer Epidemiol Biomarkers Prev 20(12):2560–2571CrossRefPubMedCentralPubMed
20.
Zurück zum Zitat Chen C, Orel SG, Harris EE, Hwang WT, Solin LJ (2003) Relation between the method of detection of initial breast carcinoma and the method of detection of subsequent ipsilateral local recurrence and contralateral breast carcinoma. Cancer 98(8):1596–1602CrossRefPubMed Chen C, Orel SG, Harris EE, Hwang WT, Solin LJ (2003) Relation between the method of detection of initial breast carcinoma and the method of detection of subsequent ipsilateral local recurrence and contralateral breast carcinoma. Cancer 98(8):1596–1602CrossRefPubMed
21.
Zurück zum Zitat Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, De Bock GH (2009) Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 114(3):403–412CrossRefPubMed Lu WL, Jansen L, Post WJ, Bonnema J, Van de Velde JC, De Bock GH (2009) Impact on survival of early detection of isolated breast recurrences after the primary treatment for breast cancer: a meta-analysis. Breast Cancer Res Treat 114(3):403–412CrossRefPubMed
22.
Zurück zum Zitat Montgomery DA, Krupa K, Jack WJ, Kerr GR, Kunkler IH, Thomas J, Dixon JM (2007) Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer 96(12):1802–1807CrossRefPubMedCentralPubMed Montgomery DA, Krupa K, Jack WJ, Kerr GR, Kunkler IH, Thomas J, Dixon JM (2007) Changing pattern of the detection of locoregional relapse in breast cancer: the Edinburgh experience. Br J Cancer 96(12):1802–1807CrossRefPubMedCentralPubMed
23.
Zurück zum Zitat Doubeni CA, Field TS, Ulcickas Yood M, Rolnick SJ, Quessenberry CP, Fouayzi H, Gurwitz JH, Wei F (2006) Patterns and predictors of mammography utilization among breast cancer survivors. Cancer 106(11):2482–2488CrossRefPubMed Doubeni CA, Field TS, Ulcickas Yood M, Rolnick SJ, Quessenberry CP, Fouayzi H, Gurwitz JH, Wei F (2006) Patterns and predictors of mammography utilization among breast cancer survivors. Cancer 106(11):2482–2488CrossRefPubMed
24.
Zurück zum Zitat Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ (2006) Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol 24(1):85–94CrossRefPubMed Keating NL, Landrum MB, Guadagnoli E, Winer EP, Ayanian JZ (2006) Factors related to underuse of surveillance mammography among breast cancer survivors. J Clin Oncol 24(1):85–94CrossRefPubMed
25.
Zurück zum Zitat Molino A, Giovannini M, Pedersini R, Frisinghelli M, Micciolo R, Mandara M, Pavarana M, Cetto GL (2004) Correlations between family history and cancer characteristics in 2256 breast cancer patients. Br J Cancer 91(1):96–98CrossRefPubMedCentralPubMed Molino A, Giovannini M, Pedersini R, Frisinghelli M, Micciolo R, Mandara M, Pavarana M, Cetto GL (2004) Correlations between family history and cancer characteristics in 2256 breast cancer patients. Br J Cancer 91(1):96–98CrossRefPubMedCentralPubMed
Metadaten
Titel
Personal or first-degree family breast cancer history: which has higher impact on tumor detection and tumor size in breast cancer
verfasst von
Fabienne Dominique Schwab
Nerbil Kilic
Dorothy Jane Huang
Seraina Margaretha Schmid
Marcus Vetter
Andreas Schötzau
Uwe Güth
Publikationsdatum
01.06.2015
Verlag
Springer Berlin Heidelberg
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 6/2015
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-014-3592-y

Weitere Artikel der Ausgabe 6/2015

Archives of Gynecology and Obstetrics 6/2015 Zur Ausgabe

Mammakarzinom: Brustdichte beeinflusst rezidivfreies Überleben

26.05.2024 Mammakarzinom Nachrichten

Frauen, die zum Zeitpunkt der Brustkrebsdiagnose eine hohe mammografische Brustdichte aufweisen, haben ein erhöhtes Risiko für ein baldiges Rezidiv, legen neue Daten nahe.

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Übersichtlicher Wegweiser“: Lauterbachs umstrittener Klinik-Atlas ist online

17.05.2024 Klinik aktuell Nachrichten

Sie sei „ethisch geboten“, meint Gesundheitsminister Karl Lauterbach: mehr Transparenz über die Qualität von Klinikbehandlungen. Um sie abzubilden, lässt er gegen den Widerstand vieler Länder einen virtuellen Klinik-Atlas freischalten.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.